DPV-004

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameDPV-004

Drug Alias Namedendritic cell-targeted immunotherapy (UbiVac/Janssen Biotech)DPV-004

ClassificationVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Application > Prophylactic vaccineBiologics > Protein drugs > Recombinant polypeptide

Mechanisms of ActionHeat-shock protein stimulants

TargetsHeat-shock protein

Therapy Area/IndicationsMouth Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesJanssen Biotech Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUbivac Janssen Biotech Inc

Active IndicationsN/A

Inactive IndicationsMouth Neoplasms

Other Information

ATC CodeN/A